Skip to main content
VISEN Pharmaceuticals logo

VISEN Pharmaceuticals — Investor Relations & Filings

Ticker · 2561 ISIN · KYG9363A1003 LEI · 254900OJ8HIP6GRV1044 HKEX Manufacturing
Open in API
Filings indexed 67 across all filing types
Latest filing 2026-05-22 Transaction in Own Shar…
Country KY Cayman Islands
Listing HKEX 2561

About VISEN Pharmaceuticals

http://www.visenpharma.com

VISEN Pharmaceuticals is an innovative biopharmaceutical company focused on the development and commercialization of paradigm-shifting therapies for endocrine diseases. The company is committed to addressing unmet medical needs within the Greater China market by providing innovative treatments and compassionate patient care. VISEN's core strategy involves leveraging advanced drug delivery platforms, which utilize prodrugs connected to carrier molecules via a linker structure. This technology enables the controlled, slow release of the unmodified prototype drug, ensuring sustained therapeutic action while the linker and carrier are safely excreted. VISEN serves as a key strategic partner for global biopharma companies seeking to commercialize high-quality endocrine assets in the region.

Recent filings

Filing Released Lang Actions
Next Day Disclosure Return
Transaction in Own Shares Classification · 95% confidence The document is a Hong Kong Exchange “Next Day Disclosure Return” (Form FF305) reporting changes in issued shares, treasury shares, on-market share repurchases, and related confirmations. It details the company’s repurchase of its own shares and treasury share transactions. Under the classification definitions, this falls squarely under “Transaction in Own Shares” (code POS), which covers share buybacks or sales of treasury shares by the issuer.
2026-05-22 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 87% confidence The document is Hong Kong Exchange Form FF305 “Next Day Disclosure Return” disclosing changes in issued shares and treasury shares, including detailed repurchase (buyback) transactions, prices, and board confirmations. This is a statutory filing for on-market share repurchases and treasury share transactions, matching our category for “Transaction in Own Shares.”
2026-05-20 English
Next Day Disclosure Return
Regulatory Filings
2026-05-19 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 92% confidence The document is a regulatory “Next Day Disclosure Return” (Form FF305) required under the Hong Kong Main Board/GEM listing rules to report share repurchases and changes in treasury shares. It provides detailed transaction data for the company’s own share buyback, including dates, quantities, prices, and confirmations of compliance. This clearly matches the definition of a “Transaction in Own Shares” report (share repurchase/issuance).
2026-05-18 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2026
Regulatory Filings
2026-05-06 English
FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, 26 JUNE 2026 AT 10:00 A.M.
Proxy Solicitation & Information Statement Classification · 98% confidence The document is a Form of Proxy for the Annual General Meeting, including voting instructions and resolutions for shareholders to appoint proxies. This is a solicitation of proxy votes and provision of meeting materials, fitting the definition of a Proxy Solicitation & Information Statement (PSI).
2026-04-28 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.